皇冠体育app

Membership

Chair

David Elliman, Clinical lead for Newborn Blood Spot听Screening Programme, Clinical Advisor to听UK NSC, Consultant Great Ormond Street Hospital

Members

• Amy Jayne McKnight, Northern Ireland Rare Disease and Congenital Anomaly Registry听(NIRADCAR)

• Anneke Lucassen, Professor of Genomic Medicine and consultant in clinical genetics at the University of Oxford and鈥�UK NSC鈥痬别尘产别谤听

• Anupam Chakrapani, Consultant in Metabolic Medicine, Great Ormond Street Hospital, and Chair of Inherited Metabolic Disorders Newborn Screening Advisory Board听

• Catherine Joynson, Head of Engagement at UK Biobank听

• Christine Cavanagh, midwife and former national manager of NHS Newborn Blood Spot Screening Programme听

• Ellen Thomas, Chief Medical Officer, Genomics England听

• Felicity Boardman, Professor of Social Science in Medicine, University of Warwick and member of鈥�UK NSC Fetal, Maternal and Child Health (FMCH)鈥痚xpert group听

• Gail Walshe, former Director of Participation and Regional Development, Contact听

• Gina Brondel, National Congenital and Rare Diseases Registration Service (NCARDRS), England听

• Graham Shortland, consultant paediatrician and vice-chair of鈥� the UK NSC听

• Heather Payne, Consultant Paediatrician, Senior Medical Officer for Maternal and Child Health, Welsh Government听

• Helen Lewis-Parmar, Consultant in Public Health, and Senior Clinical Lead for Antenatal and Newborn Screening, Vaccination and Screening Directorate, NHS England听

• Jane Fisher, Director, Antenatal Results and Choices (ARC), patient and public voice (PPV) member of鈥�FMCH鈥痚xpert group听

• Jim Bonham, Laboratory Advisor to the鈥疦HS Newborn Blood Spot鈥疭creening Programme听

• Liz Robinson, Newborn Pathway Senior Development Manager,鈥疦HSE听

• Llion Davies,鈥疌ongenital Anomaly Register and Information Service (CARIS), Public Health Wales NHS Trust听

• Mariska Leeflang, Full Professor, Epidemiology and Data Science, University of Amsterdam听

• Nick Meade, Director of Policy, Genetic Alliance UK听

• Oliver Rivero-Arias, Associate Professor and Senior Health Economist, University of Oxford, and member of鈥�FMCH鈥痚xpert group听

• Rachael Wood, Congenital Conditions and Rare Diseases Registration and Information Service for Scotland (CARDRISS)听

• Rachel Knowles, Chair of the Antenatal and Newborn (ANNB) Research, Innovation and Development Advisory Committee (RIDAC), Principal Clinical Research Fellow at UCL and Clinical Advisor to the鈥疦BS鈥痵creening programme at NHS England听

• Robin Lachmann, Consultant in Inherited Metabolic Disease, National Hospital for Neurology and Neurosurgery, London, National Specialty Advisor for Metabolic Disorders, and member of鈥�FMCH鈥痚xpert group听

• Sarah Stevens,鈥疦ational Congenital Anomaly and Rare Disease Registration Service (NCARDRS),鈥疦HSE听

• Sharon Hillier, Director, Screening Division, Public Health Wales,鈥�UK NSC鈥痬ember and chair of the鈥�FMCH鈥痚xpert group听

• Sian Taylor-Phillips, Professor of Population Health, Warwick Medical School, University of Warwick,鈥�UK NSC鈥痬ember and chair of鈥�UK NSC鈥痳esearch and methodology group (RMG)听

• Stuart Moat, Consultant Clinical Biochemist, Director of the Wales Newborn Screening Laboratory and Clinical Lead for the Metabolic Biochemistry Laboratory, University Hospital of Wales听

• Susan Spillane, Deputy Director, Health Technology Assessment, Health Information and Quality Authority Ireland听

Participant observers听

• Amanda Hogan, Newborn and SCT pathway implementation lead, Vaccinations and Screening Directorate, ANNB Screening Programmes听

• Carol Beattie, Northern Ireland Senior Medical Officer听

• David Tucker, CARIS, Public Health Wales NHS Trust听

• Ellen Crushell, Consultant Paediatrician, Republic of Ireland听听

• Helen Tutt, Policy Lead for Screening, Welsh Government听

• Lisa Douet, National Institute for Health and Care Research (NIHR)听

• Ray Smith, Head of National Screening Policy, DHSC听

• Tasmin Sommerfield, Consultant in Public Health Medicine for National Screening Programmes, National Clinical Advisor for Screening, NHS National Services Scotland

• Tsitsi Muchayingeyi, Screening Policy Lead, DHSC

Terms of reference

BSTG terms of reference.

Meetings

皇冠体育app BSTG met for the first time on 29 April 2022.

BTSG discussions feed into policy development and are therefore confidential.听

However, the group publishes summary meeting notes so they may be shared for input and discussion by interested stakeholders.听听

皇冠体育app BTSG provides updates on its work and outputs at the UK NSC Fetal, Maternal and Child Health (FMCH) group meetings 3 times a year.